Rebecca Jean Martin

US Patent:

8614255, Dec 24, 2013

Filed:

Aug 21, 2008

Appl. No.:

12/195878

Inventors:

Charles D. Blizzard - Westwood MA, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel Leblanc - Wellesley MA, US
Mark Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US

Assignee:

Civitas Therapeutics, Inc. - Chelsea MA

International Classification:

A01N 25/00
A61K 47/00
A61K 9/50

US Classification:

514778, 514781, 514958, 514970, 424499

Abstract:

The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

US Patent:

20080063722, Mar 13, 2008

Filed:

Aug 14, 2007

Appl. No.:

11/838468

Inventors:

Kevin Ward - Arlington MA, US
Thean Yeoh - Foxboro MA, US
Rebecca Martin - Blacksburg VA, US
Charles Blizzard - Westwood MA, US

Assignee:

Advanced Inhalation Research, Inc. - Cambridge MA

International Classification:

A61K 9/14
A61K 33/14
A61P 31/16

US Classification:

424489000, 424680000

Abstract:

The present invention is related to pharmaceutical formulations and methods of treating a subject afflicted with the influenza virus, the method includes administering to the respiratory tract of the patient particles that include more than about 5% to about 50% weight percent (wt %) of a neuraminidase inhibitor. The particles are delivered to the patient's pulmonary system, including the upper airways, central airways and deep lung.

US Patent:

20220296612, Sep 22, 2022

Filed:

Nov 4, 2021

Appl. No.:

17/519119

Inventors:

- Ardsley NY, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel LeBlanc - Wellesley MA, US
Mark A. Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US

International Classification:

A61K 31/58
A61K 9/00
A61K 9/16
A61K 45/06
A61K 31/13
A61K 47/36
A61K 38/29

Abstract:

The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

US Patent:

20160151393, Jun 2, 2016

Filed:

Dec 4, 2015

Appl. No.:

14/959684

Inventors:

- Chelsea MA, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel LeBlanc - Wellesley MA, US
Mark A. Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US

International Classification:

A61K 31/58
A61K 38/29
A61K 9/00

Abstract:

The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

US Patent:

20140148424, May 29, 2014

Filed:

Nov 19, 2013

Appl. No.:

14/084550

Inventors:

- Chelsea MA, US
Michael M. Lipp - Framingham MA, US
Kevin L. Ward - Arlington MA, US
Rachel Ryznal - North Oxford MA, US
Daniel Leblanc - Wellesley MA, US
Mark Tracy - Arlington MA, US
Rebecca Martin - Blacksburg VA, US

Assignee:

Civitas Therapeutics, Inc. - Chelsea MA

International Classification:

A61K 47/36
A61K 31/58

US Classification:

514174

Abstract:

The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.